Trastuzumab pamirtecan

Antibody–drug conjugate

Also known as DB-1303

Filedunder review

Evidence outlook · regulatory review

HER2-Positive Breast Cancer: application under NMPA review

NMPA accepts BLA for trastuzumab pamirtecan (DB-1303) (2026-04-09). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT06265428: Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3Endometrial Cancer · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Endometrial Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1/2 (2)
HR+/HER2- Metastatic Breast Cancer
Other / comorbidity
NCT05150691 · DualityBio Inc.
2022-01-31 – 2027-10 · HER2-positive Advanced Solid Tumor
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for HER2-Positive Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Pamirtecan: this drugPhase 3Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistReliable signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)Phase 3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 3Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BizrolertinibPhase 2/3Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2/3Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
EvorpaceptPhase 2Protein / enzyme therapeuticCD47not yet gradedNo reviewed efficacy summary in this indication
HRS-4508
Phase 2(overall)
Small moleculeHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
177Lu-DWJ155
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
BBO-10203
Phase 1(overall)
Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BL-M17D1
Phase 1(overall)
Antibody–drug conjugateHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
KJ015
Phase 1(overall)
Multispecific antibodyHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
MT-304
Phase 1(overall)
RNA / oligonucleotideHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
NVL-330
Phase 1(overall)
Small moleculeHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
GSK6855547
—(overall)
Small moleculeHER2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab pamirtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
August 2027 (1)
Phase 1/2HER2-positive Advanced Solid TumorRecruiting
Est. primary completion 2027-08 · NCT05150691 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-12 · NCT06265428 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2028-03 · NCT06340568 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08 · NCT06827236 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 October 2026Topline resultDYNASTY-Breast02 Phase 3 (NCT06018337) met its primary PFS endpoint vs chemotherapy; the companies call the benefit limited
DualityBio Inc. · Source ↗
9 April 2026Filing acceptedNMPA accepts BLA for trastuzumab pamirtecan (DB-1303)
CN, NMPA · DualityBio · Source ↗